Evidence map›Paper›PMID 38564670›Full record

ArticleMicrobiology spectrum2024

Xiaolong Miao, Peng Jiang, Xiaotong Zhang, Xinqiang Li, Zelai Wu, Yuancong Jiang, Han Liu, Weixun Xie, Xinwei Li, Bingfeng Shi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Therapeutic Potential ofJournal of microbiology and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Xiaolong Miao *Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Peng Jiang *Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaotong ZhangMedical department, Qingdao Eighth People's Hospital, Qingdao, China.
Xinqiang LiOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zelai WuDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Yuancong JiangDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Han LiuDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Weixun XieDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Xinwei LiOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Bingfeng ShiDepartment of Chemistry, Zhejiang University, Hangzhou, Zhejiang, China.
Jinzhen CaiOrgan Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.ORCID 0000-0001-5414-1050
Weihua GongDepartment of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-3221-4316
Qingdao University · CNSecond Affiliated Hospital of Zhejiang University · CNQingdao Eighth People's Hospital · CNZhejiang Chinese Medical University · CNZhejiang University · CN

Funding

MOST | National Natural Science Foundation of China (NSFC) No. 81870306
6 · The paper itself

Abstract

Solid organ transplantation is a crucial treatment for patients who have reached the end stage of heart, lung, kidney, or liver failure. However, the likelihood of developing cancer post-transplantation increases. Additionally, primary malignant tumors remain a major obstacle to the long-term survival of transplanted organs. Therefore, it is essential to investigate effective therapies that can boost the immune system's ability to combat cancer and prevent allograft rejection. We established a mouse orthotopic liver tumor model and conducted allogeneic heterotopic heart transplantation. Various treatments were administered, and survival curves were generated using the Kaplan-Meier method. We also collected graft samples and measured inflammatory cytokine levels in the serum using an inflammatory array. The specificity of the histochemical techniques was tested by staining sections. We administered a combination therapy of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and IMPORTANCE: We observed that the combination of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) dual inhibitor BEZ235 and

Indexed as

Heart TransplantationLacticaseibacillus rhamnosusTOR Serine-Threonine KinasesAnimalsDisease Models, AnimalGraft RejectionGraft SurvivalLiver NeoplasmsMaleMiceMice, Inbred BALB CMice, Inbred C57BLPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsmTOR protein, mousePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsTOR Serine-Threonine Kinasesallograft rejectionLactobacillus rhamnosus HN001PI3K/mTOR dual inhibitorprimary liver cancer

Identifiers

PMID38564670
PMCPMC11064485
OpenAlexW4393570995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.